Search

everythinglearnresearchcommunity

for

Search:↓

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

Young men are advised to delay hair transplants until after age 25, using finasteride, minoxidil, and dermarolling to manage hair loss. Concerns about unethical doctors highlight the need for careful planning.

The conversation discusses whether starting treatments like finasteride or dutasteride early in hair loss leads to better regrowth results. One user implies that early treatment is indeed more effective, while another regrets not starting treatment sooner due to permanent hair loss.

Starting Minoxidil now won't affect future Finasteride gains; they work differently and can be used together. It's suggested to start Minoxidil to maintain hair health until Finasteride can be started, and consider additional treatments like Ketoconazole shampoo, derma rolling, and rosemary oil for support.

Hair loss treatments like Minoxidil, finasteride, and RU58841 are discussed, with mention of a new product called Finjuve. There is skepticism about finding a perfect solution, but supportive treatments are expected to improve.

The post is about a user's progress pictures of their hair loss over a span of 4.5 years. They did not use finasteride or minoxidil for their hair loss treatment.

A 19-year-old shares progress in hair loss treatment from April to August 2025, using oral minoxidil, finasteride, dutasteride, and topical flutamide, minoxidil, dutasteride, and caffeine. The user seeks feedback and suggestions, with encouragement to continue the treatment.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

A 37-year-old is starting minoxidil and finasteride to address hair thinning. They are hopeful for positive results after seeing others' success.

The user has been using finasteride for two years to stabilize hair loss and is considering adding oral minoxidil for volume. They are also contemplating switching to dutasteride and possibly getting a hair transplant for better results.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

A 49-year-old male has been using finasteride for over two years, experiencing slow but steady hair regrowth without side effects, and is considering a hair transplant. He is hesitant to add minoxidil due to potential side effects and application hassle.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A clinical trial in Australia offers $20,000 for participation, aiming to regrow hair and reverse grey hair. Participants must not have used hair treatments recently and must visit a Melbourne clinic regularly over 18 months.

Long term Finasteride users and whether or not they have noticed improvements after two years of use, with other treatments such as Minoxidil and dermarolling also discussed. Some replies suggest that improvement is possible even beyond the two year mark while others caution against believing studies backed by the Post-Finasteride Foundation.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

A 36-year-old man is considering starting oral finasteride and minoxidil, using ketoconazole shampoo, and possibly getting a 3000-graft FUE hair transplant. He previously had scalp micropigmentation but is now exploring medication due to fewer concerns about side effects.

The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.

HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

A 27-year-old man's experience with taking Finasteride to treat hair loss and the positive side effects he has experienced, such as improved skin. The user also shared their journey of how they were scared away from taking Finasteride due to fear of possible side effects before eventually deciding to take it.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

A user shared their baseline bloodwork results before starting Finasteride 1mg every other day, seeking comparison with others who have done similar tests. They are interested in any changes observed after beginning the treatment.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.

The conversation is about regretting not starting hair loss treatments like finasteride earlier, with some users considering beginning treatment now. Specific treatments mentioned are finasteride (Fin) and minoxidil (Min).

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.